Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shakila Meshkat

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
NPJ Digital Medicine|February 16, 2026
Reimagining psychiatric care with agentic AI: promise, challenges, and a roadmap forwardDivya Sharma, Shakila Meshkat, Argyrios Perivolaris, et al.
Journal of Affective Disorders|August 9, 2023
Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorderShakila Meshkat, Kayla M Teopiz, Joshua D Di Vincenzo, et al.
Journal of Affective Disorders|September 1, 2022
The association between stage of treatment-resistant depression and clinical utility of ketamine/esketamine: A systematic reviewAnastasia Levinta, Shakila Meshkat, Roger S McIntyre, et al.
Journal of Affective Disorders|July 17, 2024
Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: A systematic reviewSabrina Wong, Gia Han Le, Shreya Vasudeva, et al.
Psychiatry and Clinical Neurosciences|October 2, 2024
Impact of psilocybin on cognitive function: A systematic reviewShakila Meshkat, Triana Juliana Tello-Gerez, Fatemeh Gholaminezhad, et al.
Neuroscience and Biobehavioral Reviews|April 17, 2025
Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic reviewShakila Meshkat, Gunjan Malik, Richard J Zeifman, et al.
Brain Injury|April 6, 2022
Boswellia serrata extract shows cognitive benefits in a double-blind, randomized, placebo-controlled pilot clinical trial in individuals who suffered traumatic brain injuryShakila Meshkat, Somayeh Mahmoodi Baram, Shima Rajaei, et al.
Journal of Psychopharmacology (Oxford, England)|May 17, 2023
Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youthNoah Chisamore, Kevork Danayan, Nelson B Rodrigues, et al.
Brain and Behavior|July 10, 2025
Efficacy and Safety of Glucagon-Like Peptide-1 Agonists for Psychiatric Symptoms: A Systematic ReviewShakila Meshkat, Corinna Di Luciano, Alyssa Swiderski, et al.
Current Medical Research and Opinion|July 2, 2024
Relationship between anhedonia and psychosocial functioning in post-COVID-19 condition: a <i>post-hoc</i> analysisSonya Liao, Kayla M Teopiz, Angela T H Kwan, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
NPJ Digital Medicine|February 16, 2026
Reimagining psychiatric care with agentic AI: promise, challenges, and a roadmap forwardDivya Sharma, Shakila Meshkat, Argyrios Perivolaris, et al.
Journal of Affective Disorders|August 9, 2023
Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorderShakila Meshkat, Kayla M Teopiz, Joshua D Di Vincenzo, et al.
Journal of Affective Disorders|September 1, 2022
The association between stage of treatment-resistant depression and clinical utility of ketamine/esketamine: A systematic reviewAnastasia Levinta, Shakila Meshkat, Roger S McIntyre, et al.
Journal of Affective Disorders|July 17, 2024
Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: A systematic reviewSabrina Wong, Gia Han Le, Shreya Vasudeva, et al.
Psychiatry and Clinical Neurosciences|October 2, 2024
Impact of psilocybin on cognitive function: A systematic reviewShakila Meshkat, Triana Juliana Tello-Gerez, Fatemeh Gholaminezhad, et al.
Neuroscience and Biobehavioral Reviews|April 17, 2025
Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic reviewShakila Meshkat, Gunjan Malik, Richard J Zeifman, et al.
Brain Injury|April 6, 2022
Boswellia serrata extract shows cognitive benefits in a double-blind, randomized, placebo-controlled pilot clinical trial in individuals who suffered traumatic brain injuryShakila Meshkat, Somayeh Mahmoodi Baram, Shima Rajaei, et al.
Journal of Psychopharmacology (Oxford, England)|May 17, 2023
Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youthNoah Chisamore, Kevork Danayan, Nelson B Rodrigues, et al.
Brain and Behavior|July 10, 2025
Efficacy and Safety of Glucagon-Like Peptide-1 Agonists for Psychiatric Symptoms: A Systematic ReviewShakila Meshkat, Corinna Di Luciano, Alyssa Swiderski, et al.
Current Medical Research and Opinion|July 2, 2024
Relationship between anhedonia and psychosocial functioning in post-COVID-19 condition: a <i>post-hoc</i> analysisSonya Liao, Kayla M Teopiz, Angela T H Kwan, et al.
Pageof 9